5-octylpyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-octylpyrimidine
• 化学式: C₁₂H₂₀N₂
• 分子量: 192.304
• InChiKey: BOBKHGIMWUQESJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-溴嘧啶 、 1-碘辛烷 在 吡啶 、 锰 、 三对苯甲基膦 、 三氟乙酸 、 cobalt(II) bromide 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 24.0h， 以70%的产率得到5-octylpyrimidine
  参考文献：
  名称：

  杂芳基溴化物的钴催化还原烷基化：一锅法获得烷基噻吩、-呋喃、-硒吩和-吡咯

  摘要：

  报道了一种实用且方便的共催化烷基化方法，可将各种烷基链轻松引入具有电子意义的有机杂芳基化合物，包括噻吩、呋喃、硒吩和吡咯。在充分优化的反应条件下，广泛的烷基化杂芳基化合物已以中等至良好的分离产率有效制备。值得注意的是，在聚合物化学和有机材料中起决定性作用的 2- 或 3- 烷基噻吩首次通过这种使用廉价钴盐作为催化剂的还原偶联方法逐步经济地合成。这种简单的合成过程避免了传统烷基化方案所需的水分不稳定有机金属试剂（RMgX 或 RZnX）的制备。

  DOI：

  10.1002/ejoc.201500784

文献信息

• Nickel-Catalyzed Cross-Electrophile Coupling with Organic Reductants in Non-Amide Solvents
  作者：Lukiana L. Anka-Lufford、Kierra M. M. Huihui、Nicholas J. Gower、Laura K. G. Ackerman、Daniel J. Weix

  DOI：10.1002/chem.201602668

  日期：2016.8.8

  coupling of aryl halides with alkyl halides has thus far been primarily conducted with stoichiometric metallic reductants in amide solvents. This report demonstrates that the use of tetrakis(dimethylamino)ethylene (TDAE) as an organic reductant enables the use of non‐amide solvents, such as acetonitrile or propylene oxide, for the coupling of benzyl chlorides and alkyl iodides with aryl halides. Furthermore

  迄今为止，芳基卤化物与烷基卤化物的亲电子交叉偶联主要是在酰胺溶剂中使用化学计量的金属还原剂进行的。该报告表明，使用四（二甲基氨基）乙烯（TDAE）作为有机还原剂可以使用非酰胺溶剂（如乙腈或环氧丙烷）将苄基氯和烷基碘与芳基卤化物偶合。此外，这些条件适用于几个易被锰还原的贫电子杂环。最后，我们证明TDAE的添加可以用作控制反应，以“保持”反应而不降低收率或催化剂活性。
• OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS
  申请人：Prosensa Technologies B.V.

  公开号：EP2870246A2

  公开（公告）日：2015-05-13
• Oligonucleotide for the Treatment of Muscular Dystrophy Patients
  申请人：Prosensa Technologies B.V.

  公开号：US20150191725A1

  公开（公告）日：2015-07-09

  The invention relates to an oligonucleotide and to a pharmaceutical composition comprising said oligonucleotide. This oligonucleotide is able to bind to a region of a first exon from a dystrophin pre-mRNA and to a region of a second exon within the same pre-mRNA, wherein said region of said second exon has at least 50% identity with said region of said first exon, wherein said oligonucleotide is suitable for the skipping of said first and second exons of said pre-mRNA, and preferably the entire stretch of exons in between.
• NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS
  申请人：The Scripps Research Institute

  公开号：US20170050941A1

  公开（公告）日：2017-02-23

  Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.
• [EN] OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS<br/>[FR] OLIGONUCLÉOTIDE POUR LE TRAITEMENT DE PATIENTS ATTEINTS DE DYSTROPHIE MUSCULAIRE
  申请人：PROSENSA TECHNOLOGIES BV

  公开号：WO2014007620A2

  公开（公告）日：2014-01-09

  The invention relates to an oligonucleotide and to a pharmaceutical composition comprising said oligonucleotide. This oligonucleotide is able to bind to a region of a first exon from a dystrophin pre-mRNA and to a region of a second exon within the same pre-mRNA, wherein said region of said second exon has at least 50% identity with said region of said first exon, wherein said oligonucleotide is suitable for the skipping of said first and second exons of said pre-mRNA, and preferably the entire stretch of exons in between.